Key Takeaways:
Bolt Biotherapeutics posted a second-quarter loss of $4.57 a share, missing the $2.97 consensus estimate as collaboration revenue collapsed 99.7%.
"The results reflect continued progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal cancer," Willie Quinn, president and chief executive officer, said. "We are currently treating patients in Cohort 4."
The clinical-stage biopharmaceutical company reported collaboration revenue of $5,000 for the quarter ended June 30, down from $1.8 million a year earlier and far below the $500,000 analysts projected. Net loss narrowed to $7.7 million from $8.6 million, while loss from operations improved to $8.4 million from $9.2 million. R&D expenses fell to $5.1 million from $7.5 million, and G&A expenses dropped to $2.4 million from $3.5 million, reflecting a prior restructuring.
Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, which Bolt expects to fund operations into the first quarter of 2027. The company recorded $808,000 in impairment charges in the first half. Total assets declined to $40.3 million from $56.7 million at year-end 2025, and stockholders' equity fell to $12.6 million from $26.5 million.
BDC-4182, a next-generation Boltbody immune-stimulating antibody conjugate targeting claudin 18.2, is the company's only active program. Patients are being treated in Cohort 4 at the 4.0 mg/kg dose, with step-up dosing used to reach higher levels safely. The rest of the pipeline, including BDC-3042 and preclinical ISAC programs targeting CEA and PD-L1, remains on hold.
The earnings miss intensifies scrutiny on a company whose cash runway extends only into early 2027. Initial BDC-4182 clinical data, expected with third-quarter results, will determine whether the drug's immune-stimulating mechanism shows efficacy in gastric and gastroesophageal cancers. Investors will also watch whether Bolt can secure partnerships around its ISAC platform to extend its financial runway.
This article is for informational purposes only and does not constitute investment advice.
